Alchemab Therapeutics secures €29.3 million as British Business Bank makes its largest life sciences investment yet
From the article
Alchemab Therapeutics, a London-based clinical-stage BioTech startup, has extended its Series A financing with €29.3 million (£25 million/$34 million) from the British Business Bank. This marks the bank’s largest investment in a life sciences company to date. This additional funding brings Alchemab’s total Series A investment to date to €127.8 million (£109 million). The company […] The post Alchemab Therapeutics secures €29.3 million as British Business Bank makes its largest life sciences investment yet appeared first on EU-Startups .
Continue reading on EU-StartupsYou might also wanna read
Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal
The Daily Upside·13d ago
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
ft.trib.al·1mo ago
Biotech venture capital roundup: Osanni Bio leads with $190M Series B
A roundup of recent venture capital financings in the biotech sector, headlined by Osanni Bio's $190 million Series B round to fund drug can
pharmaphorum.com·13d agoLigaChem Bio Secures 14.1 Billion Won Milestone From Ono
Seoul Economic Daily·6h ago
UK Quantum Biomedical Hub Awarded £902,000 for Clinical Sensing and Imaging Hardware Development
The UK National Quantum Biomedical Research Hub (Q-BIOMED) has received £902,000 ($1.2 million USD) from the EPSRC through the government's
iq.fp2.dev·1mo ago
Coinbase CEO Brian Armstrong's Biotech Startup Newlimit Raises $435M, Valuation Triples to $3.1B
Newlimit, the longevity biotech co-founded by Coinbase CEO Brian Armstrong, raised $435 million in a Series C round led by Founders Fund, tr
news.bitcoin.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.